Table 1.
Table summarizing the H1299 and H1299-LKB1 KO 1 clone (here reported as LKB1 KO 1) IC50 of the eleven hit compounds from the drug library screening.
| DRUG | CLASS | H1299 IC50 (μM) | LKB1 KO 1 IC50 (μM) | IC50 H1299 / IC50 LKB1 KO 1 |
|---|---|---|---|---|
| Birinapant | IAP inhibitor | >5 | 0.527 (0.466–0.596) |
≥9.48 |
| 6-Mercaptopurine | Antimetabolite | >5 | 0.212 (0.184–0.244) |
≥2.36 |
| Clofarabine | Antimetabolite | 0.717 (0.559–0.954) |
0.332 (0.289–0.385) |
2.16 |
| Floxuridine | Antimetabolite | 0.106 (0.065–0.178) |
0.054 (0.038–0.789) |
1.95 |
| Pitavastatin Calcium | HMG-CoA reductase inhibitor | 3.114 (1.681–13.159) |
1.687 (1.028–3.877) |
1.84 |
| Fostamatinib | SYK inhibitor | 4.380 (3.904–5.156) |
2.660 (2.506–2.819) |
1.65 |
| Chloroxine | Antibacterial | 3.399 (3.138–3.682) |
3.100 (2.878–3.326) |
1.10 |
| Disulfiram | ADLH-inhibitor | 0.241 (0.136–0.412) |
0.289 (0.159–0.514) |
0.83 |
| Chlorhexidine HCl | Antiseptic | 0.747 (0.626–0.876) |
1.942 (1.792–2.101) |
0.39 |
| Cobimetinib | MEK inhibitor | >4 | >4 | – |
| Pimasertib | MEK inhibitor | >4 | >4 | – |
For each compound the drug class, the IC50 in the two cell lines and the ratio between the IC50 in the H1299 and H1299-LKB1 KO 1 clone are indicated.